DBV Technologies – the French company pioneering Epicutaneous Immunotherapy (EPIT or “patch therapy”) for a number of food allergies – announced today they completed a Phase III study for their Viaskin Peanut therapy.
The blinded portion of their study, entitled REALISE (REAL Life Use and Safety of EPIT) was designed to assess the safety and routine clinical use of Viaskin Peanut 250 mcg for the treatment of peanut-allergic children four to 11 years of age, including patients with a history of severe anaphylaxis.
Dr Jacqueline Pongracic, Principal Investigator of REALISE, said: “This novel study is a critical step forward in the development of Viaskin Peanut, and allows us to focus on the safety profile of this potential treatment in routine medical practice. For children and their caregivers who face the burden of coping with peanut allergy, we know that having a safe treatment is paramount.”
The company plans to announce the results of the trial next month and has patch therapies for milk and egg in various stages of their development pipeline.